IOLCP Declares ₹1 Interim Dividend; Q3 FY26 Results Announced
IOL Chemicals and Pharmaceuticals Limited announced its Q3 FY26 results with total income at ₹585.68 crore and net profit after tax at ₹20.58 crore. For the nine months ended Dec 31, 2025, income was ₹1719.15 crore and net profit after tax was ₹84.54 crore. The company declared an interim dividend of ₹1 per share, with a record date of February 17, 2026.
The announcement includes financial results and a dividend declaration, which are material information for investors, impacting their investment decisions. The impact is medium as it is a routine quarterly result and an interim dividend.
The declaration of an interim dividend and the release of financial results, which show positive income and profit figures compared to previous periods, contribute to a positive sentiment.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors, following a recommendation from the Audit Committee and approval in their meeting held on February 11, 2026, declared an interim dividend of ₹1 per equity share (50%) for the financial year 2025-26. The record date for this interim dividend has been fixed as February 17, 2026.
For the quarter ended December 31, 2025, IOLCP reported a total income from operations of ₹585.68 crore. The Net Profit after tax for the same period stood at ₹20.58 crore. For the nine months ended December 31, 2025, the total income from operations was ₹1719.15 crore, with a Net Profit after tax of ₹84.54 crore. These results were subjected to a limited review by the statutory auditors, who issued an unmodified report.
The company has published these financial results in leading newspapers including Business Standard, Financial Express, Economic Times, and Punjabi Jagran on February 12, 2026. The full financial results are also available on the stock exchange websites (BSE and NSE) and the company's website.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.